Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat hypertension and heart failure, continues executing its 3-year strategic plan, « BAPAIs Fast Growth ».
The Company just obtained agreement from the Ethics Committee of Lisburn (United Kingdom) to start a new clinical study with extended-release firibastat tablets in order to select the final pharmaceutical formulation of the drug as early as 2019.
This clinical study will assess the pharmacokinetic parameters of firibastat in healthy subjects after a single dose of different extended-release tablets of firibastat and compare them with those obtain with the current formulation (immediate release capsules). The goal is to select a firibastat tablet formula that allows a once-daily treatment to replace the current twice-daily regimen.
The development of a once-daily pharmaceutical formulation dosing is important for firibastat because it will optimize patient adherence to treatment and simplify the development of firibastat associations with other antihypertensives agents.
The clinical study will be conducted in the United Kingdom by Quotient Sciences which Quantum Genomics selected for their expertise in pharmaceutical development and clinical pharmacology, the quality of its infrastructure and its presence in the United States and Europe. The results of this study will be available in the second quarter of 2019.
Upcoming events
November 10, 2018 Presentation of the top-line results from the NEW-HOPE trial to be held
at the annual conference of the American Heart Association in Chicago.
November 12, 2018 Press release - Top-line results from the NEW-HOPE trial.
Investors conference call.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on its 20-plus years of basic and clinical research at some of the largest French laboratories: the French National Institute of Health and Medical Research (INSERM), the French National Centre for Scientific Research (CNRS), the Collège de France, and Paris-Descartes University. The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with heart failure dies within five years).
Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).
For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn
Contact information
| Quantum Genomics | |
| Jean-Philippe Milon CEO +33 (0)1 85 34 77 70 | jean-philippe.milon@quantum-genomics.com | Marc Karako CFO-Investor Relations +33 (0)1 85 34 77 70 | marc.karako@quantum-genomics.com |
| So Bang (European Investor & Media Contact) | |
| Samuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr | Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.fr |
| Edison Advisors (U.S. Investor Contact) | LifeSci Public Relations (U.S. Media Contact) |
| Tirth Patel Investor Relations +1 (646) 653-7035 | tpatel@edisongroup.com | Michael Tattory Media Relations and Scientific Communications +1 (646) 751-4362 | mtattory@lifescipublicrelations.com |
https://www.actusnews.com/documents_communiques/ACTUS-0-55607-alqgc-comite-ethique-lp-ph1-version-us-final.pdf
© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
